Moditen (Fluphenazine Hydrochloride)

Fluphenazine hydrochloride, the active ingredient in Moditen, is a phenothiazine typical antipsychotic presented as an oral tablet for oral use. It is employed to manage schizophrenia and acute psychotic disorders in adult patients. GNH USA supplies Moditen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moditen, a phenothiazine antipsychotic, is used to treat disorders characterized by dopamine dysregulation. - Schizophrenia: reduces hallucinations, delusions and thought disorder. - Acute psychotic disorders: rapidly controls agitation, hallucinations and severe psychotic symptoms. - Schizoaffective disorder: helps stabilize both mood and psychotic features.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, akathisia. - Sedation or drowsiness. - Dry mouth and reduced salivation. - Constipation or gastrointestinal upset. - Blurred vision. - Weight gain.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: persistent involuntary movements. - Agranulocytosis: severe neutropenia. - Seizures. - Severe hypotension or cardiovascular collapse. - Cardiac arrhythmias, including QT prolongation.

Before initiating therapy, clinicians should consider several safety measures. - Monitor for extrapyramidal symptoms: assess motor function regularly. - Assess cardiovascular status: watch for orthostatic hypotension and arrhythmias. - Evaluate psychiatric history: screen for depression or suicidal ideation. - Use caution in elderly patients with dementia-related psychosis due to increased mortality risk. - Avoid abrupt discontinuation: taper dose to reduce withdrawal effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Fluphenazine may interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - CNS depressants: additive sedation and respiratory depression. - Antihypertensive agents: may cause excessive hypotension. - QT‑prolonging drugs: increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may mask extrapyramidal symptoms. - Lithium: potential for increased neurotoxicity. - Carbamazepine or other enzyme inducers: may reduce fluphenazine plasma concentrations.